Trial Profile
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ENDEAVOR
- Sponsors Amgen; Onyx Pharmaceuticals
- 01 Oct 2022 Results of post-hoc pooled analysis assessing cardiovascular risk factors and cardiovascular disease data from four clinical studies: ASPIRE, ARROW, FOCUS, ENDEAVOR published in the Clinical Lymphoma, Myeloma & Leukemia
- 13 Sep 2022 Results of post hoc analysis assessing safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma published in the European Journal of Haematology
- 20 May 2021 Results of a matching adjusted indirect treatment comparison analysis and data were pooled from three clinical studies: CANDOR , ENDEAVOR and OPTIMISMM presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research